IL-13R alpha 2 Antibody [Allophycocyanin]

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Interleukin-13 Receptor alpha 2 (IL-13 R alpha 2), also CD213 alpha 2, is a 55-57 kDa member of the type I cytokine receptor family of molecules. Human IL-13 R alpha 2 is a 354 amino acid (aa) type I transmembrane glycoprotein that contains a 317 aa extracellular domain (ECD) characterized by three fibronectin type III domains (aa 27-343). It is expressed by a limited number of cell types, principally those associated with the respiratory system. These cells include fibroblasts, type II alveolar and visceral smooth muscle cells, pseudostratified ciliated epithelium, goblet cells and possibly monocytes. Notably, IL-13 R alpha 2 is often found to be intracellular, rather than plasma membrane expressed, and this may reflect storage deposits that can be quickly accessed when needed. IL-13 R alpha 2 is one of two IL-13Rs that bind IL-13. The principal, but low affinity receptor for IL-13 is a 65 kDa transmembrane protein termed IL-13 R alpha 1. Following binding to IL-13, this protein complexes with an adjacent IL-4 R alpha receptor on the cell surface to form a high affinity, functional receptor signaling complex for IL-13. Within this system, IL-13 R alpha 2 has been described as a "decoy receptor" that binds to circulating IL-13, rendering it unavailable for IL-13 R alpha 1 binding. Supporting this view is the fact that there does not appear to be any canonical signaling motif in IL-13 R alpha 2s short cytoplasmic tail, and the fact that soluble IL-13 R alpha 2 will bind to IL-13 and neutralize its effects on target cells in culture. The latter point is of particular importance when it is recognized that IL-13 R alpha 2 has a naturally circulating soluble splice form in mouse. Studies in human, however, suggest a more complicated situation. First, it is unclear if human actually has circulating IL-13 R alpha 2. Unlike in mouse, there is no potential alternative splice form in human that could generate a soluble isoform. And while MMP-8 has been identified as a potential mediator of IL-13 R alpha 2 proteolytic cleavage, such activity would appear to generate rather small quantities of soluble IL-13 R alpha 2. As a transmembrane protein, IL-13 R alpha 2 is suggested to interact with IL-4 R alpha , and this likely will result in a downregulation of IL-13 activity. Thus, IL-13 R alpha 2, while not a decoy receptor, could act as a negative modulator of IL-13 signaling. On the other hand, the cytoplasmic tail of IL-13 R alpha 2 is now believed to stimulate AP-1 activity, and the IL-13:IL-13 R alpha 2 transmembrane complex has been identified as a component of a larger signaling receptor complex for the GH-18 (Glycosyl Hydrolase 18) family member YKL40/Chi3L1. As such, IL-13 R alpha 2 is likely to exhibit multiple actions in a system and species-specific manner. Over aa 27-342, human and mouse IL-13 R alpha 2 share 64% aa sequence identity.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 1 application: CAR-T (Flow Cytometry).

Showing Publication 1 - 1 of 1.

Publication using FAB614A	Applications	Species
Bielamowicz K, Fousek K, Byrd T, Samaha H, Mukherjee M, Aware N, Wu M, Orange J, Sumazin P, Man T, Joseph S, Hegde M, Ahmed N Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol, 2018-03-27;20(4):506-518. 2018-03-27 [PMID: 29016929] (CAR-T (Flow Cytometry), Human)	CAR-T (Flow Cytometry)	Human

Array FAB614A

• IL-13R alpha 2 Antibodies
• IL-13R alpha 2 ELISA Kits
• IL-13R alpha 2 Lysate
• IL-13R alpha 2 Proteins
• IL-13R alpha 2 Proteins and Enzymes
• IL-13R alpha 2 ELISAs